WO2007146224A2 - Thérapie combinée pour le traitement d'une pollakiurie, d'une miction impérieuse et d'une incontinence urinaire - Google Patents

Thérapie combinée pour le traitement d'une pollakiurie, d'une miction impérieuse et d'une incontinence urinaire Download PDF

Info

Publication number
WO2007146224A2
WO2007146224A2 PCT/US2007/013683 US2007013683W WO2007146224A2 WO 2007146224 A2 WO2007146224 A2 WO 2007146224A2 US 2007013683 W US2007013683 W US 2007013683W WO 2007146224 A2 WO2007146224 A2 WO 2007146224A2
Authority
WO
WIPO (PCT)
Prior art keywords
urinary
bis
ethoxy
fluorophenyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/013683
Other languages
English (en)
Other versions
WO2007146224A3 (fr
Inventor
Keith M. Gottesdiener
Stuart A. Green
Euan Macintyre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of WO2007146224A2 publication Critical patent/WO2007146224A2/fr
Publication of WO2007146224A3 publication Critical patent/WO2007146224A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Definitions

  • compositions for the treatment of urinary frequency, urinary urgency and urinary incontinence comprising a selected antagonist of the NK-I receptor or a pharmaceutically acceptable salt thereof and an anti-muscarinic agent or a pharmaceutically acceptable salt thereof.
  • This invention concerns combination therapy for urinary frequency, urinary urgency and urinary incontinence wherein one of the active agents is a selected antagonist of the NK-I receptor or a pharmaceutically acceptable salt thereof and another is an anti-muscarinic agent or a pharmaceutically acceptable salt thereof.
  • the function of the lower urinary tract is to store and periodically release urine. This requires the orchestration of storage and micturition reflexes which involve a variety of afferent and efferent neural pathways, leading to modulation of central and peripheral neuroeffector mechanisms, and resultant coordinated regulation of sympathetic and parasympathetic components of the autonomic nervous system as well as somatic motor pathways. These proximally regulate the contractile state of bladder (detrusor) and urethral smooth muscle, and urethral sphincter striated muscle.
  • Urinary frequency urinary urgency is a disorder characterized by frequent and generally inappropriate strong urges to urinate. From a pathophysiologic point of view, urinary frequency, urinary urgencyis most often associated with detrusor instability ("overactive bladder"), which may be intrinsic or may occur secondary to neurological conditions such as stroke or spinal cord injury. Urinary frequency, urinary urgencyaffects approximately 16% of both men and women; particularly in women, urinary frequency, urinary urgencyoften is accompanied by urinary incontinence, which is defined as socially inappropriate, involuntary loss of urine. Urgency with or without incontinence has been shown to negatively impact both social and medical well-being, and represents a significant burden in terms of annual direct and indirect healthcare expenditures.
  • urge incontinence is "a disease of bladder sensors". See Klein, L.A.: Urge incontinence can be a disease of bladder sensors. J Urol., 139: 1010-10-14, 1998.
  • afferent activity from the bladder is mediated largely by the myelinated A ⁇ -fibers that pass through the spinal tracts to the brainstem and then to the pontine micturition center. After spinal disruption, a different type of afferent pathway emerges that is mediated by unmyelinated C-fibers that are sensitive to capsaicin. It is thought that these primary afferent C-fibers drive the spinal segmental reflex pathway and may be involved in pathological conditions of the bladder including overactivity and incontinence.
  • TK tachykinins
  • NK receptor antagonists NK receptor antagonists
  • C-fiber neurotoxins capsaicin and resinferatoxin
  • NK 1 and/or NK 2 receptor antagonists may induce the same effects as capsaicin by inhibiting the sensorial input from the bladder to the spinal cord, thus increasing the threshold to initiate micturition.
  • NKi and NK 2 receptor antagonists have been studied in various animal models of bladder function. Using a cyclophosphamide-induced model of bladder overactivity, it has been shown that two NKi antagonists (GR 82334 and RP 67580) increased the volume threshold after i.t, but not i.v. administration. A moderate response in this model was also observed with the NK 2 antagonist SR 48968 (10 nmol/rat), however the i.v. co-administration of NKi and NK 2 , antagonists did not modify urodynamic variables in either vehicle- or cyclophosphamide-treated rats. See Lecci, A., Giuliani, S., Santicioli, P., Maggi, CA.
  • GR 82334 blocked capsaicin- induced micturition reflex in rats. Importantly, at the same doses proved effective in the chemonociceptive reflex, GR 82334 did not affect the micturition reflex induced by bladder filling or the force of contraction induced by perineal pinching. See Lecci, A., Giuliani, S., Maggi, CA. Effect of the NK-I receptor antagonist GR 82334 on reflexly-induced bladder contractions. Life Sciences, 51; 277- 280, 1992.
  • TAK-637 0.1, 0.3, 1 and 3 mg/kg i.v.
  • TAK-637 at 3mg/kg i.v. did not inhibit the micturition reflex induced by electrical stimulation of the rostral brainstem near the locus coeruleus, indicating that it does not impair the efferent pathways of the micturition reflex.
  • TAK-637 increases bladder storage capability without inhibiting the voiding function of the lower urinary tract, presumably by inhibiting the afferent pathway of the micturition reflex rather than the efferent pathway.
  • the systemic administration of TAK-637 decreased the number but not the amplitude of distension-induced rhythmic bladder contractions in guinea pig, an effect which was also observed in animals with severed spinal cords.
  • TAK-637 also inhibited the micturition reflex induced by topical application of capsaicin (which stimulates primary afferent nerve endings in the bladder wall) onto the surface of the bladder dome.
  • TAK-637 inhibits sensory transmission from the bladder evoked by both physiological and nociceptive stimuli by blocking tachykinin NK 1 receptors, almost certainly at the level of the spinal cord. Furthermore, TAK-637 inhibits the spinal vesico-vesical reflex induced by electrical stimulation of the proximal cut end of the pelvic nerve in spinal animals, but not bladder contractions induced by electrical stimulation of the distal cut end of the nerve. Tissue bath studies showed that TAK-637 had no effect on carbachol or electrical field stimulation induced contractions of isolated bladder strips, whereas other drugs used for abnormally frequent micturition inhibited both contractions. These results suggest that TAK-637 inhibits the micturition reflex by acting, at least in part, on NKi receptors in the spinal cord, a mechanism of action clearly different from antimuscarinics or spasmolytics
  • NK-I receptor antagonists and in particular, those whose use is claimed herein, are also believed to be useful in the treatment of Lower Urinary Tract Symptoms (LUTS).
  • LUTS Lower Urinary Tract Symptoms
  • this invention concerns a pharmaceutical composition for the treatment of urinary frequency, urinary urgency and urinary incontinence comprising a therapeutically effective amount of a selected antagonist of the NK-I receptor or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of an anti-muscarinic agent or a pharmaceutically acceptable salt thereof.
  • this invention concerns combination therapy and pharmaceutical compositions the treatment of urinary frequency, urinary urgency and urinary incontinence wherein one of the active agents is a selected antagonist of the NK-I receptor or a pharmaceutically acceptable salt thereof and another is an anit-muscarinic agent or a pharmaceutically acceptable salt thereof.
  • this invention concerns a pharmaceutical composition for the treatment of a disease selected from urinary frequency, urinary urgency or urinary incontinence have two active agents: a therapeutically effect amount of
  • NK-I receptor antagonists are selected from group (a).
  • NTC-I receptor antagonist is: or a pharmaceutically acceptable salt thereof.
  • the NK-1 receptor antagonists are selected from group (b).
  • group (b) Within this genus is a sub-genus wherein the NK-I receptor antagonist is:
  • NK-I receptor antagonists are selected from group (c).
  • the anti-muscarinic agents include tolterodine, oxybutynin, trospium, vamicamide, solifenacin, propiverine, S-oxybutynin, temiverine, sanctura, staybla, fesoterodine, SVT40776, 202405 by GlaxoSmithKline, TD6301, RBX9841, DDP200, and PLDl 79.
  • the anti-muscarinic agents also include trospium chloride, darifenacin and imidafenacin (KRP-197).
  • these drugs may be administered orally or topically in standard or extended release forms, such as extended release tolterodine, extended relesase oxybutynin and transdermal oxybutynin.
  • this invention concerns a pharmaceutical composition for the treatment of a disease selected from urinary frequency, urinary urgency or urinary incontinence comprising a therapeutically effect amount of a selected NK-I receptor antagonist, as discussed above and a therapeutically effective amount of an anti-muscarinic agent selected from the group consisting of tolterodine, oxybutynin, trospium, vamicamide, solifenacin, propiverine, S-oxybutynin, temiverine, sanctura, staybla, fesoterodine, SVT40776, 202405 by GlaxoSmithKline, TD6301, RBX9841, DDP200, and PLD 179.
  • a disease selected from urinary frequency, urinary urgency or urinary incontinence
  • an anti-muscarinic agent selected from the group consisting of tolterodine, oxybutynin, trospium, vamicamide, solifenacin, propiverine, S-oxybutynin, temiverine,
  • the anti-muscarinic agent is selected from the group consisting of trospium chloride, darifenacin and imidafenacin.
  • the anti-muscarinic agent is selected from the group consisting extended release tolterodine, extended relesase oxybutynin and transdermal oxybutynin.
  • compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • compositions for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
  • Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • Oily suspensions may be formulated by suspending the active ingredient in a suitable oil.
  • Oil-in-water emulsions may also be employed.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
  • compositions of the present compounds may be in the form of a sterile injectable aqueous or oleagenous suspension.
  • the compounds of the present invention may also be administered in the form of suppositories for rectal administration.
  • creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of the present invention may be employed.
  • the compounds of the present invention may also be formulated for administered by inhalation.
  • the compounds of the present invention may also be administered by a transdermal patch by methods known in the art.
  • compositions containing compounds of the present invention may be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy.
  • unit dosage form is taken to mean a single dose wherein all active and inactive ingredients are combined in a suitable system, such that the patient or person adminstering the drug to the patient can open a single container or package with the entire dose contained therein, and does not have to mix any components together from two or more containers or packages.
  • Typical examples of unit dosage forms are tablets or capsules for oral administration, single dose vials for injection, or suppositories for rectal administration. This list of unit dosage forms is not intended to be limiting in any way, but merely to represent typical examples in the pharmacy arts of unit dosage forms.
  • compositions containing compounds of the present invention may also be presented as a kit, whereby two or more components, which may be active or inactive ingredients, carriers, diluents, and the like, are provided with instructions for preparation of the actual dosage form by the patient or person administering the drug to the patient.
  • kits may be provided with all necessary materials and ingredients contained therein, or they may contain instructions for using or making materials or components that must be obtained independently by the patient or person administering the drug to the patient.
  • pharmaceutically acceptable it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • administering a should be understood to mean providing a compound of the invention to the individual in need of treatment in a form that can be introduced into that individual's body in a therapeutically useful form and therapeutically effective amount, including, but not limited to: oral dosage forms, such as tablets, capsules, syrups, suspensions, and the like; injectable dosage forms, such as IV, BvI, or DP, and the like; transdermal dosage forms, including creams, jellies, powders, or patches; buccal dosage forms; inhalation powders, sprays, suspensions, and the like; and rectal suppositories.
  • therapeutically effective amount refers to a sufficient quantity of the compounds of the present invention, in a suitable composition, and in a suitable dosage form to treat or prevent the noted disease conditions.
  • both the compound of the present invention and the other active agent(s) will be administered to a patient, within a reasonable period of time.
  • the compounds may be in the same pharmaceutically acceptable carrier and therefore administered simultaneously. They may be in separate pharmaceutical carriers such as conventional oral dosage forms which are taken simultaneously.
  • the term "combination" also refers to the case where the compounds are provided in separate dosage forms and are administered sequentially. Therefore, by way of example, one active component may be administered as a tablet and then, within a reasonable period of time, the second active component may be administered either as an oral dosage form such as a tablet or a fast-dissolving oral dosage form.
  • a “fast dissolving oral formulation” is meant, an oral delivery form which when placed on the tongue of a patient, dissolves within about 10 seconds.
  • “reasonable period of time” is meant a time period that is not in excess of about 1 hour. That is, for example, if the first active component is provided as a tablet, then within one hour, the second active component should be administered, either in the same type of dosage form, or another dosage form which provides effective delivery of the medicament.
  • the compounds of this invention may be administered to patients (humans and animals, including companion animals, such as dogs, cats and horses) in need of such treatment in dosages that will provide optimal pharmaceutical efficacy.
  • the dose required for use in any particular application will vary from patient to patient, not only with the particular compound or composition selected, but also with the route of administration, the nature of the condition being treated, the age and condition of the patient, concurrent medication or special diets then being followed by the patient, and other factors which those skilled in the art will recognize, with the appropriate dosage ultimately being at the discretion of the attendant physician.
  • a suitable dosage level of the NK-I receptor antagonist or pharmaceutically acceptable salts thereof is about 0.001 to 50 mg/kg per day, in particular about 0.01 to about 25 mg/kg, such as from about 0.05 to about 10 mg/kg per day.
  • the dosage range will generally be about 0.5 to 1000 mg per patient per day, which may be administered in single or multiple doses.
  • the dosage range will be about 0.5 mg to 500 mg per patient per day; more preferably about 0.5 mg to 200 mg per patient per day; and even more preferably about 1 mg to 10 mg or 5 mg to 50 mg per patient per day.
  • Specific dosages of the compounds of the present invention, or pharmaceutically acceptable salts thereof, for administration include 1 mg, 5 mg, 10 mg, 30 mg, 100 mg, and 500 mg.
  • compositions of the present invention may be provided in a formulation comprising about 0.5 mg to 1000 mg active ingredient; more preferably comprising about 0.5 mg to 500 mg active ingredient; or 0.5 mg to 250 mg active ingredient; or 1 mg to 10 or 100 mg active ingredient.
  • Specific pharmaceutical compositions comprise about 1 mg, 5 mg, 10 mg, 30 mg, 100 mg, and 500 mg of active ingredient.
  • a suitable dosage level of tolterodine includes that presently approved for the drug, such a 1 , 2 or 4 mg of tolterodine tartrate, once or twice a day.
  • NK-I receptor antagonists of group (a) and methods of making same are disclosed in the Examples section, hereinunder.
  • NK-I receptor antagonists of group (b) and methods for making same are disclosed in WP2005/073191, published August 11, 2005.
  • the resulting slurry was heated to reflux for 12 h, cooled to rt, and water (23 L) was added.
  • the vessel was rinsed with an additional 6 L of water and the reaction mixture further diluted with an additional 46 L of water.
  • To the homogeneous solution was added 9 L of cone. HCl to adjust the pH to 1 and the solution aged for 2.5 h.
  • the slurry was then filtered and the cake washed with 17 L of water and 17 L of toluene.
  • the solid was then dried at 60 0 C for 48 h, providing 2-(4-fluoro- phenyl)- 1,3-cyclopentanedione as a light tan solid.
  • the heterogeneous reaction mixture was then heated to 100 0 C, generating 25 psig pressure in the vessel.
  • the reaction was aged at 100 0 C for 12 h, cooled to rt, and diluted with 150 mL of water.
  • the resulting homogeneous mixture was distilled to remove THF and then heated to 50 0 C.
  • the aqueous solution was then slowly acidified using cone. HCl until a final pH of 3 was obtained (10.6 mL).
  • the slurry was cooled to rt and filtered.
  • the resulting POBr 3 solution was then added drop-wise to the slurry, and the mixture was heated to 65 0 C for 1.5 h and cooled to rt.
  • the reaction mixture was quenched with IN KOH to a final pH of ⁇ 8.0 and aged for 30 min. During the quench the precipitation of insolubles occurs at pH ⁇ 4 which turns to an oily mass around pH 7-7.5.
  • the bottom oily layer and aqueous layer were separated.
  • the top MeCN layer containing the product was filtered over a small plug of solka floe, which was then rinsed with one bed volume of MeCN.
  • the combined MeCN layers were then concentrated to a final volume of 500 mL.
  • the toluene layer was then azeotropically dried (50 0 C, 25 inHg) to a final volume of 21 L (KF 130 ug/mL) and used in the next step.
  • To the toluene solution was added 820 niL (3.6 mol) of 25 wt% NaOMe in MeOH at 50 0 C and the mixture heated to 75 0 C for 1 h.
  • the mixture was then cooled to 50 0 C and 17 L of water, 1 L of MeOH, and 4.5 L of 6N NaOH was added. The mixture was stirred at 20-25 °C overnight. The layers were separated, and the toluene layer discarded.
  • the aqueous layer was then washed with 15 L of MTBE and the MTBE layer discarded.
  • the aqueous layer was then made acidic with cone. HCl (2.1 L, pH 1).
  • the mixture was extracted with 40 L of BPAC.
  • the B? AC layer containing the product (1.35 kg, 69% assay) was then treated with 500 g of Darco for 30 min at 25 0 C and filtered over a pad of solka floe, rinsing the pad with and additional 5 L of IPAC.
  • the IPAC solution was then azeotropically dried (45 0 C, 25 inHg) to a final volume of 15 L (KF ⁇ 200) and cooled to 20 0 C.
  • the combined heptane extracts were then washed twice with water (2 x 100 L) and concentrated to a volume of 100 L. Negligible product was lost to the heptane washes, the acidified aqueous layer and the combined aqueous washes.
  • To the concentrated heptane solution was added MTBE (10 L) and triethylamine at 45 0 C. The resulting solution was then allowed to cool to 20 0 C overnight during which time the ether-acid TEA salt crystallized from solution. The slurry was therefore cooled to 5 0 C before filtering.
  • the filtration liquors contained 1.3% of the desired product (( 1 R),(2R),(3 S))-3 -(( 1 R)- 1 -(3 ,5-bis(trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl)cyclopentane- carboxylic acid
  • TEA salt The crude TEA salt (12.96 kg) was dissolved in toluene (100 L) and then washed with IM HCl (55 L) to remove the triethylamine. The resulting organic layer was then washed with saturated aqueous NaHCO 3 (50 L) followed by water (50 L).
  • the resulting toluene solution was concentrated to 20 L and heptane (90 L) was added. The resulting solution was warmed to 50 0 C, triethylamine (1.1 equiv.) was added and the batch was cooled to 30 0 C over 1 h. The slurry that had formed was then allowed to cool to 20 0 C overnight.
  • Method B Into a solution of ((lR),(2R),(3S))-3-((lR)-l-(3,5-bis(trifluoromethyl)phenyI)ethoxy)-2- (4-fluorophenyl)cyclopentanecarboxylic acid from Intermediate 1 in methanol was bubbled HCl gas until the solution was saturated. The solution was aged for 16 hr at rt and was then concentrated in vacuo. The residue was diluted with water and extracted twice with ethyl acetate. The ethyl acetate layers were each successively washed with brine containing sodium bicarbonate solution, combined, and dried over sodium sulfate. Removal of solvent in vacuo and purification by FC (20—40% ethyl acetate/hexanes) afforded the title intermediate.
  • Step B (( 1 R),(2R),(3S))-3-(( IR)- 1 -(3,5-bis(Trifluoromethyl)phenyl)ethoxy)-2-(4- fluorophenyl)cyclopentanemethanol
  • Method B To a suspension of ((lR),(2R),(3S))-3-((lR)-l-(3,5-bis(trifluoromethyl)pheny])ethoxy)- 2-(4-fluorophenyl)cyclopentanecarboxylic acid ⁇ A TEA salt (25 gm, 48.5 mmol) (see Step A) suspended in toluene (60 mL) and cooled in an ice bath was slowly added 1 M borane:THF complex in THF (97 mL). After the initial gas evolution had ceased, the reaction was heated to 75 C for 1 hr. The reaction was again cooled in an ice bath prior to slow addition of water to quench excess borane.
  • Step C ((lR),(2R),(3S))-3-((lR)-l-(3,5-bis(Trifluoromethyl)phenyl)ethoxy)-2-(4- fluorophenyl)cyclopentanecarboxaldehyde
  • oxalyl chloride 1.5 mL
  • methylene chloride 40 mL
  • DMSO 2.4 mL
  • Step D (( 1 S),(2R),(3R))- 1 -(( 1 R)- 1 -(3,5-bis(Trifluoromethyl)pheny l)ethoxy)-2-(4-fluorophenyl>-
  • Step E (( 1 S),(2R),(3R))- 1 -(( 1 R)- 1 -(3,5-bis(Trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl> 3-((lR and lS)-l,4-dihydroxybut-l-yl)cyclopentane
  • Step F Methyl 4-((( 1R),(2R),(3 S))-3-(( 1 R> 1 -(3,5-bis(trifluoromethyl)phenyl)ethoxy)-2-(4- fluorophenyl)cyclopent- 1 -yl)-4-oxobutanoate
  • Step G (5R and 5S)-5-(((lR),(2R),(3S))-3-((lR)-l-(3,5-bis(Trifluoromethyl)phenyl)ethoxy)-2- (4-fluorophenyl)cyclopent- 1 -yl)- 1 -methy lpyrrolidin-2-one
  • Step A N-Methyl,N-methoxy (( 1 R),(2R),(3 S))-3-(( 1 R)- 1 -(3 ,5-bis(trifluoromethyl)phenyl)- ethoxy)-2-(4-fluorophenyl)cycIopentanecarboxamide
  • Step B (( 1 S),(2R),(3R)> 1 -(( 1 R)- 1 -(3 ,5-bis(Trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyI)- 3-(l-oxopent-4-en-l-yl)cyclopentane
  • Step C ((l S),(2R),(3R))-l-((lR)-l-(3,5-bis(Trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl)-
  • Method B was done essentially the same as Method A except that only 1 eq. of 7M ammonia in methanol and 10 eq. of ammonium acetate are used in place of excess ammonia and ammonium chloride. The yield of each CBZ isomer is about 40%.
  • Step D (5R)-5-((( 1 R),(2R),(3 S))-3-(( 1 R> 1 - ⁇ 3,5-bis(Trifluoromethyl)phenyl)ethoxy)-2-(4- fluoropheny ⁇ cyclopentan-l-yl ⁇ l-benzyloxycarbonylpyrrolidin ⁇ -one (from lower CBZ (IR) isomer)
  • Method A A solution of ((lS),(2R),(3R))-l-((lR)-l-(3 J 5-bis(trifluoromethyl)phenyl)ethoxy)-2-(4- fluorophenyl)-3-((lR)-l-(benzyloxycarbonylamino)pent-4-en-l-yl)cyclopentane (lower (IR) isomer from Step C) (600 mg, 0.94 mmol) in methanol (30 mL) was cooled in a dry ice/acetone bath to -70 0
  • Method B was done essentially the same as Method A except that on larger scale the crude ozonolysis product in acetone was slowly added to excess Jones Reagent in acetone at less than 30 0 C. After 1 hr, the excess Jones Reagent was quenched with isopropanol. Work-up and purification was done as in Method A.
  • Step E (5R>5-((( 1 R),(2R),(3 S))- 1 -(( 1 R)- 1 -(3 ,5-bis(Trifluoromethyl)phenyl)ethoxy)-2-(4- fluorophenyl)cyclopentan-l-yl)pyrrolidin-2-one (lower (R) isomer)
  • Step D-E ((1S),(2R),(3R))-1- ((lR)-l-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl)-3-((lS)-l-(benzyloxycarbonyl- amino)pent-4-en-l-yl)cyclopentane (higher (IS) isomer from Example 3, Step C) (60 mg, 0.094 mmol) was converted to the title compound.
  • Step B (( 1 S),(2R),(3R)> 1 -(( 1 R)- 1 -(3,5-bis(Trifluoromethyl)phenyl)ethoxy>2-(4-fluorophenyl)-
  • Step C N-Acetyl (5R)-5-(((lR),(2R),(3S))-3-((lR)-l-(3,5-bis(Trifluoromethyl)phenyl)ethoxy)-2-
  • Step D Using essentially the same procedure as in Example 3, Step D, but using the lower Rf (( 1 S),(2R),(3R))- 1-((1R)-I -(3,5-bis(trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl)-3-((2R)-2- (acetylamino)hex-5-en-2-yl)cyclopentane (800 mg, 1.4 mmol) from Step B, the title intermediate was obtained after FC (15-30% ethyl acetate/hexanes).
  • Step D (5R>5-((( 1 R),(2R),(3 S))-3-(( 1 R)- 1 -(3 ,5-bis(Trifiuoromethyl)phenyl)ethoxy)-2-(4- fluorophenyl)cyclopentan-l-yl)-5-niethylpyrrolidin-2-one
  • Step B (3R,5R and 3S,5R)-5-(((lR),(2R),(3S))-3-((lR>l-(3,5-bis(Trifluoromethyl)phenyl)- ethoxy)-2-(4-fluorophenyl)cyclopentan-l-yl)-3-hydroxypyrrolidin-2-one
  • HPLC/MS Faster
  • m/e 520 (M+l)
  • Rt 3.73 min
  • Step A (5R>5-((( 1 R),(2R),(3 S))-3- ⁇ ( 1 R)- 1 -(3 ,5-bis(Trifluoromethyl)phenyl)ethoxy)-2-(4- fluorophenyl)cyclopentan-l-yl)-l-benzyloxycarbonyl-5-methylpyrrolidin-2-one
  • Step B (3R.5R and 3S,5R)-5-(((lR),(2R),(3S))-3-((lR)-l-(3,5-bis(Trifluoromethyl)- phenyl)ethoxy)-2-(4-fl uorophenyl)cyclo ⁇ entan- 1 -yl)- 1 -benzy loxycarbonyl-3 -hydroxy-5- methylpyrrolidin-2-one
  • Step C (3R,5R and 3S,5R)-5-(((lR),(2R),(3S))-3-((lR>l-(3,5-bis(TrifluoromethyI)phenyl)- ethoxy)-2-(4-fluorophenyl)cyclopentan-l-yl)-3-hydroxy-5-methylpyrrolidin-2-on
  • Step A (5R)-5-((( 1 R),(2R),(3 S))-3-(( 1 R)- 1 -(3,5-bis(Trifluoromethyl)phenyl)ethoxy)-2-(4- fluorophenyl)cyclopentan-l-yl)-3-oxoypyrrolidin-2-one
  • Step B (3R,5R and 3S,5R>5-(((lR),(2R),(3S»3-((lR)-l-(3,5-bis(Trifluoromethyl)phenyl)- ethoxy)-2-(4-fluorophenyl)cyclopentan-l-yl)-3-hydroxy-3-methylpyrrolidin-2-one
  • Step B (3R,5R)-5-(((lR) ) (2R),(3S))-3-((lR)-l-(3,5-bis(Trifluoromethyl)phenyl)ethoxy)-2-(4- fluorophenyl)cyclopentan-l-yl)-3-azidopyrroIidin-2-one
  • 3S,5R>5-(((lR),(2R) ) (3S))-3-((lR)-l-(3,5-bis(trifluoromethyl)phenyl)- ethoxy)-2-(4-fluorophenyl)cyclopentan-l-yl)-3-mesylpyrrolidin-2-one (170 mg, 0.284 mmol) from Step A (higher Rf) in DMF (2 mL) was added sodium azide (185 mg).
  • Step C (3R,5R)-5-(((lR),(2R),(3S))-3-((lR)-l-(3,5-bis(TrifluoromethyI)phenyl)ethoxy)-2-(4- fluorophenyl)cyclopentan-l-yl)-3-aminoopyrrolidin-2-one hydrochloride salt
  • a solution of (3R,5R)-5-(((lR),(2R),(3S))-3-((lR)-l-(3,5- bis(trifluoromethyl)phenyl)ethoxy)-2-(4-fluorophenyl)cyclopentan-l-yl)-3-azidopyrrolidin-2-one (112 mg) from Step B was hydrogenated over 20% Pd(OH) 2 /C (40 mg) as in Example 3, Step E, in the presence of 2N HCl in ether (0.20 mL) to afford the title product HCl salt after filtration and
  • Step A (3R,5R)-5-(((lR),(2R),(3S))-3-(( 1 R)-I -(3,5-bis(Trifluoromethyl)phenyl)ethoxy)-2-(4- fluorophenyOcyclopent-l-yO-l ⁇ -dibenzyloxycarbonyl ⁇ -methylpyrrolidin ⁇ -one
  • Step B (3R,5R>5-(((lR),(2R),(3S))-3-((lR)-l-(3,5-bis(TrifluoromethyI)phenyl)ethoxy)-2-(4- fluorophenyOcyclopent-i-yl ⁇ -carboxyO-methylpyrrolidin ⁇ -one
  • Step C (3R,5 R)-5-((( 1 R),(2R),(3 S))-3-(( 1 R)- 1 -(3,5-bis(Trifluoromethyl)phenyl)ethoxy)-2-(4- fluorophenyOcyclopent-l-yl ⁇ -benzyloxycarbonylamino-S-methylpyrroIidin ⁇ -one
  • 3R,5R -5-(((lR),(2R),(3S))-3-((lR)-l-(3,5-bis(trifluoromethyl)phenyl)- erhoxy ⁇ -fluorophenyOcycloDent-l-yl ⁇ -carboxy-S-methylpyrrolidin ⁇ -one
  • the toluene layers were each successively washed with cold brine containing some sodium bicarbonate solution, combined, and dried over sodium sulfate. About 2/3 of the solvent was removed in vacuo without heating to afford a dry toluene solution of the acyl azide intermediate. (Note: It is very important to keep the solution cold to prevent rearrangement to the isocyanate prior to complete drying by azeotroping any water and acetone during removal of the toluene. Also, the residual isobutanol must be removed at this time.
  • acyl azide should not be concentrated to dryness due to the exothermic loss of nitrogen during the subsequent rearrangement.
  • Step D (3R,5R)-5-(((lR),(2R),(3S))-3-((lR)-l-(3,5-bis(Trifluoromethyl)phenyl)ethoxy)-2-(4- fluorophenyl)c yclopent- 1 -y l)-3-amino-3-methylpyrrolidin-2-one hydrochloride salt
  • a solution of (3R,5R>5-((( 1 R),(2R),(3 S)>3-(( 1 R)- 1 -(3,5-bis(trifluoromethyl)- phenyl)ethoxy)-2-(4-fluorophenyl)cyclopent-l-yl)-3-benzyloxycarbonylamino-3-methylpyrrolidin-2-one (12.5 gm, 18.7 mmol) (prepared as in Step C) in methanol (100 mL) and 2N HCl in ether (19 mL) was hydrogenated over 20% Pd

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des compositions destinées au traitement d'une pollakiurie, d'une miction impérieuse et d'une incontinence urinaire, contenant un antagoniste choisi du récepteur NK-1 ou un sel pharmaceutiquement acceptable de cet antagoniste, ainsi qu'un agent anti-muscarinique ou un sel pharmaceutiquement acceptable de cet agent. La présente invention concerne une thérapie combinée pour le traitement d'une pollakiurie, d'une miction impérieuse et d'une incontinence urinaire, l'un des principes actifs étant un antagoniste choisi du récepteur NK-1 ou un sel pharmaceutiquement acceptable de cet antagoniste et l'autre principe actif étant un agent anti-muscarinique ou un sel pharmaceutiquement acceptable de cet agent.
PCT/US2007/013683 2006-06-12 2007-06-07 Thérapie combinée pour le traitement d'une pollakiurie, d'une miction impérieuse et d'une incontinence urinaire Ceased WO2007146224A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81274306P 2006-06-12 2006-06-12
US60/812,743 2006-06-12

Publications (2)

Publication Number Publication Date
WO2007146224A2 true WO2007146224A2 (fr) 2007-12-21
WO2007146224A3 WO2007146224A3 (fr) 2008-02-14

Family

ID=38832453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/013683 Ceased WO2007146224A2 (fr) 2006-06-12 2007-06-07 Thérapie combinée pour le traitement d'une pollakiurie, d'une miction impérieuse et d'une incontinence urinaire

Country Status (1)

Country Link
WO (1) WO2007146224A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008030389A3 (fr) * 2006-09-06 2008-12-04 Merck & Co Inc Formulations pharmaceutiques liquides et semi-liquides pour l'administration orale d'un amide substitué
CN102218063A (zh) * 2011-04-12 2011-10-19 贵州神奇制药有限公司 盐酸丙哌维林药物的制备方法和产品及其检测方法
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
WO2014209962A1 (fr) 2013-06-24 2014-12-31 Tigercat Pharma, Inc. Utilisation de serlopitant, antagoniste du récepteur nk -1, dans le traitement du prurit
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750549A (en) * 1996-10-15 1998-05-12 Merck & Co., Inc. Cycloalkyl tachykinin receptor antagonists
JP4458853B2 (ja) * 2002-03-13 2010-04-28 シェーリング コーポレイション Ｎｋ１アンタゴニスト
US6974820B2 (en) * 2002-11-06 2005-12-13 Bridge Pharma, Inc. Methods for treating urinary incontinence and other disorders using trospium

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008030389A3 (fr) * 2006-09-06 2008-12-04 Merck & Co Inc Formulations pharmaceutiques liquides et semi-liquides pour l'administration orale d'un amide substitué
CN102218063A (zh) * 2011-04-12 2011-10-19 贵州神奇制药有限公司 盐酸丙哌维林药物的制备方法和产品及其检测方法
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
WO2014209962A1 (fr) 2013-06-24 2014-12-31 Tigercat Pharma, Inc. Utilisation de serlopitant, antagoniste du récepteur nk -1, dans le traitement du prurit
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9381188B2 (en) 2013-06-24 2016-07-05 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9474741B2 (en) 2013-06-24 2016-10-25 Menlo Therapeutics Inc. Use of NK-1 receptor antagonists in pruritus
US9486439B2 (en) 2013-06-24 2016-11-08 Menlo Therapeutics Inc. Use of NK-1 receptor antagonist serlopitant in pruritus
US9737508B2 (en) 2013-06-24 2017-08-22 Menlo Therapeutics Inc. Use of NK-1 receptor antagonists in pruritus
US9737507B2 (en) 2013-06-24 2017-08-22 Menlo Therapeutics Inc. Use of NK-1 receptor antagonist serlopitant in pruritus
US9968588B2 (en) 2013-06-24 2018-05-15 Menlo Therapeutics Inc. Use of NK-1 receptor antagonists in pruritus
US9974769B2 (en) 2013-06-24 2018-05-22 Menlo Therapeutics Inc. Use of NK-1 receptor antagonist serlopitant in pruritus
US10278952B2 (en) 2013-06-24 2019-05-07 Menlo Therapeutics Inc. Use of NK-1 receptor antagonists in pruritus
US10278953B2 (en) 2013-06-24 2019-05-07 Menlo Therapeutics Inc. Use of NK-1 receptor antagonist serlopitant in pruritus
US10617671B2 (en) 2013-06-24 2020-04-14 Menlo Therapeutics Inc. Use of NK-1 receptor antagonist serlopitant in pruritus
US10702499B2 (en) 2013-06-24 2020-07-07 Menlo Therapeutics Inc. Use of NK-1 receptor antagonists in pruritus
US11026920B2 (en) 2013-06-24 2021-06-08 Vyne Therapeutics Inc. Use of NK-1 receptor antagonist serlopitant in pruritus

Also Published As

Publication number Publication date
WO2007146224A3 (fr) 2008-02-14

Similar Documents

Publication Publication Date Title
KR101769999B1 (ko) Ｎｍｄａ 수용체 조절제 및 그의 용도
RU2621049C2 (ru) Модуляторы рецептора нмда и их применение
JP4629657B2 (ja) １１β−ヒドロキシステロイドデヒドロゲナーゼ１型化活性化合物
DE69201956T2 (de) Pyrrolidin- und thiazolidinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
DE60313330T2 (de) Synergistische Zusammensetzungen enthaltend einen alpha-2-delta-Liganden, kombiniert mit einem PDEV-Inhibitor zur Behandlung von Schmerz
CA3220005A1 (fr) Modulateurs de recepteurs couples a la proteine g
EP1802623A1 (fr) Composes spiro actifs du type a- hydroxysteroide deshydrogenase de type 1
KR20150110784A (ko) 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
EA018225B1 (ru) Соединения оксадиазоантрацена для лечения диабета
KR20090102867A (ko) Ｎｋ1 수용체 길항제 및 나트륨 채널 차단제를 포함하는 제약 조성물
KR102354790B1 (ko) P-치환된 비대칭 우레아 및 그의 의학적 용도
KR20140048239A (ko) 아미노 프로판디올 유도체, 제조방법 및 약제학적 조성물 및 사용
WO2007146224A2 (fr) Thérapie combinée pour le traitement d'une pollakiurie, d'une miction impérieuse et d'une incontinence urinaire
TW202330513A (zh) )抑制劑及其使用方法
CN104854083B (zh) 氨基环丁烷衍生物、其制备方法及其用作药物的用途
US20100048545A1 (en) Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity
EP3609870A1 (fr) N-aryléthyl-2-aminoquinoléine-4-carboxamides substitués et leur utilisation
WO2002022568A1 (fr) Acides $g(b)-thio-amines
KR20080035658A (ko) 신경병증 및 관련 장애를 치료하기 위한 방법 및 조성물
EP3454657A1 (fr) Composé de dihydroisoxazole à utiliser pour lutter contre les poux de mer
EP1326826A1 (fr) Utilisation d'acides amines dans le traitement de la douleur
EP1937264B1 (fr) Polytherapie destinee au traitement de la pollakiurie, de la miction imperieuse et de l'incontinence urinaire
CN101252926A (zh) 用于预防和治疗肥胖症及相关综合征的化合物与组合物
KR100424997B1 (ko) 알콜중독증치료를위한피롤리딘유도체의용도
EP3148969A1 (fr) Composés pour le traitement de crises épileptiques et d'autres troubles et affections du système nerveux central

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07809454

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07809454

Country of ref document: EP

Kind code of ref document: A2